Skip to main content

Advertisement

SpringerLink
Log in

Secondary Cytoreductive Surgery in Patients with Platinum-Sensitive Recurrent Ovarian Cancer

  • Gynecology
  • Published:
Annals of Surgical Oncology Aims and scope Submit manuscript

ABSTRACT

Background

Secondary surgical cytoreduction (SCR) represents a promising therapeutic strategy for patients affected by ovarian cancer disease recurrence. The aim of this prospective observational trial was to analyze the role of SCR in patients with platinum-sensitive ovarian cancer.

Methods

Patients with platinum-sensitive ovarian cancer underwent SCR by a single surgical team. Clinical and oncologic data were prospectively recorded. A total of 47 patients underwent SCR from 1999 to 2003.

Results

The mean operating time was 210 minutes, and mean blood loss was 500 mL. The most frequent surgical procedures carried out were splenectomy, lymphadenectomy, bowel resection, and extensive peritonectomy. Optimal cytoreduction was achieved in 41 patients. Thirty-seven patients had no visible tumor at the end of SCR. Overall median survival was 49 months. Patients who achieved optimal residual disease had a median survival of 61 months, whereas patients who had residual disease >1 cm had a median survival of 19 months.

Conclusions

Positive CA-125 (cancer antigen 125) was identified as a negative prognostic factor at multivariate analysis. After careful selection, optimal cytoreduction can be achieved in most patients who are subjected to SCR with acceptable morbidity. Residual tumor and CA-125 represent the most important prognostic factors.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

FIG. 1.
FIG. 2.

Similar content being viewed by others

References

  1. Jemal A, Tiwari RC, Murray T, et al. American Cancer Society Cancer statistics, 2004. CA Cancer J Clin 2004; 54:8–29

    PubMed  Google Scholar 

  2. Young JA, Garretson F, Westlake DL, Illig WP, Vogl SE. Intraperitoneal cisplatin with intravenous cyclophosphamide and doxorubicin for previously untreated stage III and IV ovarian carcinoma. Cancer Invest 1989; 7:565–70

    PubMed  CAS  Google Scholar 

  3. Jemal A, Murray T, Samuels A, Ghafoor A, Ward E, Thun MJ. Cancer statistics, 2003. CA Cancer J Clin 2003; 53:5–26

    Article  PubMed  Google Scholar 

  4. Bristow RE, Tomacruz RS, Armstrong DK, Trimble EL, Montz FJ. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol 2002; 20:1248–59

    Article  PubMed  Google Scholar 

  5. Griffiths CT. Surgical resection of tumor bulk in the primary treatment of ovarian carcinoma. Natl Cancer Inst Monogr 1975; 42:101–4

    PubMed  CAS  Google Scholar 

  6. Wharton JT, Herson J. Surgery for common epithelial tumors of the ovary. Cancer 1981; 48:582–9

    Article  PubMed  CAS  Google Scholar 

  7. Hacker NF, Berek JS, Lagasse LD, Nieberg RK, Elashoff RM. Primary cytoreductive surgery for epithelial ovarian cancer. Obstet Gynecol 1983; 61:413–20

    PubMed  CAS  Google Scholar 

  8. McGuire WP. High-dose chemotherapy and autologous bone marrow or stem cell reconstitution for solid tumors. Curr Probl Cancer 1998; 22:135–77

    Article  PubMed  CAS  Google Scholar 

  9. Berek JS, Hacker NF, Lagasse LD, Poth T, Resnick B, Nieberg RK. Second-look laparotomy in stage III epithelial ovarian cancer: clinical variables associated with disease status. Obstet Gynecol 1984; 64:207–12

    PubMed  CAS  Google Scholar 

  10. Rubin SC, Randall TC, Armstrong KA, Chi DS, Hoskins WJ. Ten-year follow-up of ovarian cancer patients after second-look laparotomy with negative findings. Obstet Gynecol 1999; 93:21–4

    Article  PubMed  CAS  Google Scholar 

  11. Berek JS, Bertelsen K, du Bois A, et al. Advanced epithelial ovarian cancer: 1998 consensus statements. Ann Oncol 1999; 10:87–92

    Article  PubMed  Google Scholar 

  12. Eisenkop SM, Friedman RL, Spirtos NM. The role of secondary cytoreductive surgery in the treatment of patients with recurrent epithelial ovarian carcinoma. Cancer 2000; 88:144–53

    Article  PubMed  CAS  Google Scholar 

  13. Zang RY, Li ZT, Tang J, et al. Secondary cytoreductive surgery for patients with relapsed epithelial ovarian carcinoma: who benefits? Cancer 2004; 100:1152–61

    Article  PubMed  Google Scholar 

  14. Petterson F. International Federation of Gynecology and Obstetrics Report. Stockholm: International Federation of Gynecology and Obstetrics, 1988; 110–51

  15. Berek JS, Hacker NF, Lagasse LD, Nieberg RK, Elashoff RM. Survival of patients following secondary cytoreductive surgery in ovarian cancer. Obstet Gynecol 1983; 61:189–93

    PubMed  CAS  Google Scholar 

  16. Morris M, Gershenson DM, Wharton JT, Copeland LJ, Edwards CL, Stringer CA. Secondary cytoreductive surgery for recurrent epithelial ovarian cancer. Gynecol Oncol 1989; 34:334–8

    Article  PubMed  CAS  Google Scholar 

  17. Janicke F, Holscher M, Kuhn W, et al. Radical surgical procedure improves survival time in patients with recurrent ovarian cancer. Cancer 1992; 70:2129–36

    Article  PubMed  CAS  Google Scholar 

  18. Segna RA, Dottino PR, Mandeli JP, Konsker K, Cohen CJ. Secondary cytoreduction for ovarian cancer following cisplatin therapy. Clin Oncol 1993; 11:434–9

    CAS  Google Scholar 

  19. Vaccarello L, Rubin SC, Vlamis V, et al. Cytoreductive surgery in ovarian carcinoma patients with a documented previously complete surgical response. Gynecol Oncol 1995; 57:61–5

    Article  PubMed  CAS  Google Scholar 

  20. Gadducci A, Iacconi P, Cosio S, Fanucchi A, Cristofani R, Riccardo Genazzani A. Complete salvage surgical cytoreduction improves further survival of patients with late recurrent ovarian cancer. Gynecol Oncol 2000; 79:344–9

    Article  PubMed  CAS  Google Scholar 

  21. Munkarah A, Levenback C, Wolf JK, et al. Secondary cytoreductive surgery for localized intra-abdominal recurrences in epithelial ovarian cancer. Gynecol Oncol 2001; 81:237–41

    Article  PubMed  CAS  Google Scholar 

  22. Scarabelli C, Gallo A, Carbone A. Secondary cytoreductive surgery for patients with recurrent epithelial ovarian carcinoma. Gynecol Oncol 2001; 83:504–12

    Article  PubMed  CAS  Google Scholar 

  23. Tay EH, Grant PT, Gebski V, Hacker NF. Secondary cytoreductive surgery for recurrent epithelial ovarian cancer. Obstet Gynecol. 2002; 99:1008–13

    Article  PubMed  Google Scholar 

  24. Pfisterer J, Harter P, Canzler U, et al. The role of surgery in recurrent ovarian cancer.Int J Gyn Cancer 2005; 15:195–198

    Article  Google Scholar 

  25. Ayhan A, Gultekin M, Taskiran C, et al. The role of secondary cytoreduction in the treatment of ovarian cancer: Hacettepe University experience. Am J Ostet Gynecol 2006; 194:49–56

    Article  Google Scholar 

  26. Chi DS, McCaughty K, Diaz JP, et al. Guidelines and selection criteria for secondary cytoreductive surgery in patients with recurrent, platinum-sensitive epithelial ovarian carcinoma. Cancer 2006; 106:1933–9

    Article  PubMed  Google Scholar 

  27. Kehoe S, Powell J, Wilson S, Woodman C. The influence of the operating surgeon’s specialisation on patient survival in ovarian carcinoma. Br J Cancer 1994; 70:1014–7

    PubMed  CAS  Google Scholar 

  28. Junor EJ, Hole DJ, McNulty L, Mason M, Young J. Specialist gynaecologists and survival outcome in ovarian cancer: a Scottish national study of 1866 patients. Br J Obstet Gynaecol 1999; 106:1130–6

    PubMed  CAS  Google Scholar 

Download references

Acknowledgment

The authors declare that there is no financial or personal conflict of interest.

Author information

Authors and Affiliations

  1. Department of Obstetrics and Gynecology, University of Rome “La Sapienza,”, Viale del Policlinico, 155, 00161, Rome, Italy

    Pierluigi Benedetti Panici MD, Antonio De Vivo MD, Filippo Bellati MD, Natalina Manci MD, Giorgia Perniola MD & Stefano Basile MD

  2. Department of Obstetrics and Gynecology, University Campus Bio-Medico of Rome, Via Longoni, 83, 00100, Rome, Italy

    Ludovico Muzii MD & Roberto Angioli MD

Authors
  1. Pierluigi Benedetti Panici MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Antonio De Vivo MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Filippo Bellati MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Natalina Manci MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Giorgia Perniola MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Stefano Basile MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Ludovico Muzii MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Roberto Angioli MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Pierluigi Benedetti Panici MD.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Benedetti Panici, P., De Vivo, A., Bellati, F. et al. Secondary Cytoreductive Surgery in Patients with Platinum-Sensitive Recurrent Ovarian Cancer. Ann Surg Oncol 14, 1136–1142 (2007). https://doi.org/10.1245/s10434-006-9273-8

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1245/s10434-006-9273-8

Keywords

Search

Navigation